Cell type-associated traits map for the [FetalHeart_Ventricle cardiomyocyte][link to cell ontology]. Due to the large number of UKBB panel traits, this figure shows the non-UKBB traits with a CSEA p (chi2) < 1e-04 as default, and users can change it to 1e-03, 1e-05, or 1e-06. For each cell type and trait association pair (shown as an edge in the figure), there may be multiple TAG sets, each defined at a different threshold. The pair with the minimum p-value is shown in the figure, with the p-value showing along each edge. The number of edges in the figure is thus less than (or equal to) the number of entries in the table below.” The association association is listed in the table at bottom, Because each trait might have multiple TAG sets defined at different thresholds, multiple rows for each cell type and trait pair with different "TAG Set Threshold" and " CSEA p (chi2)" (the last two columns).
Table. List of Cell type-associated traits pairs for [FetalHeart_Ventricle cardiomyocyte]. If the network above is too complicated. the users could obtain the association information from the table at bottom. Because each trait has multiple TAG sets defined at different thresholds, there may be multiple rows for each cell type and trait pair with different "TAG Set Threshold" and " CSEA p (chi2)" (the last two columns). Users could identify the most significant association by sorting “CSAE p (chi2)” column.
Trait Name |
Trait Full Name |
Panel |
Author |
Year |
Cases* |
Controls |
TAG Set Threshold |
CSEA p (chi2) |
Blood Pressure | Blood Pressure | MTC | Ehret | 2011 | NA | 69395 | 1.00e-5 | 3.59e-2 |
Neuroticism | Neuroticism | MTC | De-Moor | 2012 | NA | 17375 | 1.00e-3 | 2.30e-2 |
Obsessive Compulsive Disorder | Obsessive Compulsive Disorder | ETC | Arnold | 2017 | 2688 | 7037 | 1.00e-3 | 3.45e-2 |
Prostate Cancer | Prostate Cancer | MTC | Yeager | 2007 | 1172 | 1157 | 1.00e-2 | 6.54e-3 |
Tetralogy Of Fallot | Tetralogy Of Fallot | MTC | Cordell | 2013 | 835 | 5159 | 5.00e-2 | 4.62e-2 |
Albuminuria | Microalbuminuria | MTC | Boger | 2011 | NA | 31580 | 5.00e-2 | 2.55e-2 |
Albuminuria | Microalbuminuria | MTC | Boger | 2011 | NA | 31580 | 1.00e-2 | 2.45e-2 |
Blood Cells | Platelet Counts | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 2.26e-2 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 1.59e-2 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-2 | 2.85e-2 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 4.30e-2 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-2 | 6.81e-3 |
BMI Smoking Adjusted | BMI Smoking Adjusted European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-5 | 4.87e-2 |
Cognitive Functions | College | MTC | Davies | 2016 | NA | 111114 | 5.00e-2 | 2.48e-2 |
Facial Shape | Mod10 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 3.31e-2 |
Facial Shape | Mod11 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.97e-2 |
Facial Shape | Mod13 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.04e-2 |
Facial Shape | Mod2 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 1.51e-2 |
Facial Shape | Mod23 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 4.81e-2 |
Facial Shape | Mod35 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.28e-2 |
Facial Shape | Mod35 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 4.19e-2 |
Facial Shape | Mod36 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.27e-2 |
Facial Shape | Mod36 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 2.47e-3 |
Facial Shape | Mod44 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 3.58e-2 |
Facial Shape | Mod45 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 1.09e-2 |
Facial Shape | Mod58 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 4.61e-2 |
Facial Shape | Mod62 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 1.24e-2 |
Facial Shape | Mod62 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 8.48e-3 |
Forced Expiratory Volume | Forced Expiratory Volume Over Forced Vital Capacity | MTC | Soler-Artigas | 2015 | NA | 38199 | 1.00e-2 | 1.83e-2 |
Forced Expiratory Volume | Forced Expiratory Volume Over Forced Vital Capacity | MTC | Soler-Artigas | 2015 | NA | 38199 | 1.00e-3 | 2.96e-2 |
Gestational Weight Gain | Early Gestational Weight Gain Offspring Variants | MTC | Warrington | 2017 | NA | 8559 | 1.00e-2 | 4.17e-2 |
Gestational Weight Gain | Total Gestational Weight Gain Maternal Variants | MTC | Warrington | 2017 | NA | 16434 | 1.00e-2 | 2.13e-2 |
Gestational Weight Gain | Total Gestational Weight Gain Offspring Variants | MTC | Warrington | 2017 | NA | 10555 | 1.00e-2 | 2.35e-2 |
Glycemic Traits BMI Corrected | Fasting Insulin Interaction With BMI | MTC | Manning | 2012 | NA | 51750 | 5.00e-2 | 3.50e-2 |
Insulin Secretion | Peak Insulin Response Adjusted For BMI And Insulin Sensitivity | MTC | Wood | 2017 | NA | 2159 | 5.00e-2 | 3.77e-2 |
Insulin Secretion | Peak Insulin Response Adjusted For BMI And Insulin Sensitivity | MTC | Wood | 2017 | NA | 2159 | 1.00e-2 | 1.93e-2 |
Intracerebral Hemorrhage | Nonlobar ICH | MTC | Woo | 2014 | 881 | 1481 | 5.00e-2 | 2.92e-2 |
Intracerebral Hemorrhage | Nonlobar ICH | MTC | Woo | 2014 | 881 | 1481 | 1.00e-2 | 3.27e-2 |
Ischaemic Stroke | Large Vessel Disease | MTC | Traylor | 2012 | 1877 | 12285 | 1.00e-2 | 2.82e-2 |
Ischaemic Stroke | Large Vessel Disease | MTC | Traylor | 2012 | 1877 | 12285 | 1.00e-3 | 4.37e-2 |
Kidney Function | Chronic Kidney Disease | MTC | Kottgen | 2010 | NA | 67093 | 1.00e-2 | 1.60e-2 |
Leptin | Leptin Adjusted For BMI | MTC | Kilpelainen | 2016 | NA | 32161 | 5.00e-2 | 3.65e-2 |
Leptin | Leptin Not Adjusted For BMI | ETC | Kilpelainen | 2016 | NA | 32161 | 5.00e-2 | 2.72e-2 |
Longevity | Age 90 Or Greater | MTC | Deelen | 2014 | 5406 | 15112 | 1.00e-3 | 2.30e-2 |
Waist Format 1 | Waist Hip Ratio Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-2 | 6.84e-3 |
Sleep | Sleep number of episodes | ETC | Jones | 2019 | NA | 84810 | 1.00e-3 | 1.19e-2 |
Postburn scar height | Postburn scar height | ETC | Wallace | 2018 | NA | 665 | 5.00e-2 | 1.52e-2 |
Postburn scar pliability | Postburn scar pliability | ETC | Wallace | 2018 | NA | 665 | 5.00e-2 | 4.42e-2 |
Nonischemic cardiomyopathy | Nonischemic cardiomyopathy | ETC | Aragam | 2018 | 1816 | 388326 | 1.00e-2 | 4.04e-2 |
Nonischemic cardiomyopathy | Nonischemic cardiomyopathy | ETC | Aragam | 2018 | 1816 | 388326 | 1.00e-3 | 1.92e-2 |
Heart failure | Heart failure | ETC | Aragam | 2018 | 6504 | 387652 | 1.00e-2 | 2.04e-2 |
Hippocampal volume | Hippocampal subfield CA3 volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 3.00e-2 |
Hippocampal volume | Hippocampal subfield CA1 volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 8.13e-3 |
IHPS | Infantile hypertrophic pyloric stenosis | ETC | Fadista | 2018 | NA | 4438 | 1.00e-3 | 4.63e-2 |
Medication use | Medication use (beta blocking agents) | ETC | Wu Y | 2019 | 31,700 | 192,324 | 1.00e-5 | 3.79e-2 |
Glomerular filtration rate | Estimated glomerular filtration rate | ETC | Wuttke M | 2019 | NA | 567,460 | 1.00e-2 | 1.60e-2 |
CKD | Chronic kidney disease | ETC | Wuttke M | 2019 | 64,164 | 561,055 | 1.00e-5 | 2.50e-2 |
Nonalcoholic Liver disease | Liver fibrosis in non-alcoholic fatty acid liver disease | ETC | Namjou B | 2019 | NA | 235 | 5.00e-2 | 3.90e-2 |
Temporal lobe volume | Temporal lobe volume | ETC | van der Lee SJ | 2019 | NA | 15,269 | 1.00e-2 | 2.91e-2 |
Temporal lobe volume | Temporal lobe volume | ETC | van der Lee SJ | 2019 | NA | 15,269 | 1.00e-3 | 7.90e-3 |
Temporal lobe volume | Temporal lobe volume | ETC | van der Lee SJ | 2019 | NA | 15,269 | 1.00e-4 | 5.75e-4 |
Left ventricular | Left ventricular end-systolic volume | ETC | Aung N | 2019 | NA | 16,920 | 5.00e-2 | 4.43e-2 |
Left ventricular | Left ventricular end-systolic volume | ETC | Aung N | 2019 | NA | 16,920 | 1.00e-2 | 1.15e-2 |
Left ventricular | Left ventricular end-systolic volume | ETC | Aung N | 2019 | NA | 16,920 | 1.00e-3 | 5.29e-3 |
Left ventricular | Left ventricular end-systolic volume | ETC | Aung N | 2019 | NA | 16,920 | 1.00e-5 | 9.99e-3 |
Left ventricular | Left ventricular ejection fraction | ETC | Aung N | 2019 | NA | 16,923 | 1.00e-3 | 1.06e-2 |
Left ventricular | Left ventricular ejection fraction | ETC | Aung N | 2019 | NA | 16,923 | 1.00e-4 | 9.48e-3 |
Left ventricular | Left ventricular mass | ETC | Aung N | 2019 | NA | 16,920 | 1.00e-2 | 1.28e-2 |
Left ventricular | Left ventricular mass | ETC | Aung N | 2019 | NA | 16,920 | 1.00e-3 | 4.03e-3 |
Left ventricular | Left ventricular end-diastolic volume | ETC | Aung N | 2019 | NA | 16,920 | 1.00e-2 | 2.49e-2 |
COVID-19 | COVID-19 UKBB EUR tested (Mixed Population) | ETC | GRASP | 2020 | 1,291 | 5,455 | 1.00e-3 | 1.73e-2 |
COVID-19 | COVID-19 UKBB EUR (Mixed Population) | ETC | GRASP | 2020 | 1,291 | 457,959 | 1.00e-3 | 1.73e-2 |
* If the number of cases is 0/NA, it means the phenotype is a continuous data type and the number of controls is the total number of samples.